Depressive disorder
Conditions
Interventions
Non-invasive Neuroregulation Treatment Group:None
Drug Stabilization Treatment Group:None
Healthy Control Group:None
Sponsors
Hangzhou Seventh People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Treatment of patients with non-traumatic neuromodulation for depression disorder Grouping Criteria: (1) Age of 18 years (including) to 65 years (including), male or female ; (2) Complies with the diagnostic criteria for DSM-5 depression disorder ; (3) Received non-traumatic neuromodulatory treatment such as transcranial magnetic stimulation, transcranial direct-current stimulation, etc. ; (4) Currently undergoing antidepressant medication treatment >= 4 weeks, with medication type and dosage stable >= 4 weeks ; (5) Understanding and voluntarily participating in this study, the person or their legal guardian consents and signs a written informed consent. 2. Medication Stability in Treatment of Patients with Depression Disorder Grouping Criteria: (1) Age of 18 years (including) to 65 years (including), male or female ; (2) Complies with the diagnostic criteria for DSM-5 depression disorder ; (3) Currently undergoing antidepressant medication treatment >= 4 weeks, with medication type and dosage stable >= 4 weeks ; (4) Understanding and voluntarily participating in this study, the person or their legal guardian consents and signs a written informed consent. 3. Healthy subjects Inclusion Criteria: (1) The age of 18 years (including) to 65 years (including), male or female; (2) Understanding and voluntarily participating in this study, with the consent and signature of a written informed consent by myself or my legal guardian; (3) No history of mental illness and mental illness in the family.
Exclusion criteria
Exclusion criteria: 1. Treatment of patients with non-traumatic neuromodulation for depression disorder Exclusion Criteria: (1) Patients who meet the diagnostic criteria for other DSM-5 mental disorders or have harmful use of psychoactive substances; (2) Patients with severe or unstable cardiovascular, respiratory, hepatic, renal, hematological, endocrine, neurological, or other systemic diseases; (3) Other circumstances deemed by the investigator as inappropriate for participation in this study. 2. Medication Stability in Treatment of Patients with Depression Disorder Exclusion Criteria: (1) Patients who meet the diagnostic criteria for other DSM-5 mental disorders or have harmful use of psychoactive substances; (2) Patients with severe or unstable cardiovascular, respiratory, hepatic, renal, hematological, endocrine, neurological, or other systemic diseases; (3) Other circumstances deemed by the investigator as inappropriate for participation in this study. (4) No history of mental illness and mental illness in the family. 3. Healthy subjects Exclusion Criteria: (1) Patients with severe or unstable cardiovascular, respiratory, hepatic, renal, hematological, endocrine, neurological, or other systemic diseases; (2) Other circumstances deemed by the investigator as inappropriate for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate of HAMD-17 (defined as >50% reduction from baseline);Core body temperature (circadian parameters, phase shift of minimum temperature);Cerebral functional indicators (changes in prefrontal cortex HbO? concentration during task and resting states);Inflammatory response markers (nicotinic acid skin reaction); | — |
Countries
China
Contacts
Public ContactDeng Wei
Hangzhou Seventh People's Hospital
Outcome results
None listed